CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 221 enrolled
Drug / intervention
Tobramycin 0.3%/Dexamethasone 0.05% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00576251
NCT00576251Phase 3Completed
CompareCT.gov

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

Alcon Research·interventional·Posted Dec 19, 2007·Updated Mar 2, 2010

In Brief

A Phase 3 clinical trial evaluating Tobramycin 0.3%/Dexamethasone 0.05% and TOBRADEX for Ocular Inflammation Associated With Blepharaconjunctivitis. Completed, enrolled 221 participants across 1 site.

Detailed Summary

The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Inflammation Associated With Blepharaconjunctivitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 19, 2007
Enrollment StartOct 1, 2007
Primary CompletionFeb 1, 2008
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.5 years ago

Interventions

Tobramycin 0.3%/Dexamethasone 0.05%drug

Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days

TOBRADEXdrug

TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days